Published in Acta Clin Belg on January 01, 1987
CD8alpha+ and CD8alpha- subclasses of dendritic cells direct the development of distinct T helper cells in vivo. J Exp Med (1999) 6.06
Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia. European Organization for Research and Treatment of Cancer--Childhood Leukemia Cooperative Group. N Engl J Med (1998) 4.95
The B-cell surface protein CD72/Lyb-2 is the ligand for CD5. Nature (1991) 2.76
Myeloid dendritic cells induce Th2 responses to inhaled antigen, leading to eosinophilic airway inflammation. J Clin Invest (2000) 2.67
Antigen-pulsed dendritic cells can efficiently induce an antibody response in vivo. J Exp Med (1992) 2.05
B lymphocytes regulate dendritic cell (DC) function in vivo: increased interleukin 12 production by DCs from B cell-deficient mice results in T helper cell type 1 deviation. J Exp Med (2000) 2.02
A clinical trial of anti-idiotype therapy for B cell malignancy. Blood (1985) 1.91
Mouse x human heterohybridomas as fusion partners with human B cell tumors. J Immunol Methods (1986) 1.73
Identification of MAGE-3 epitopes presented by HLA-DR molecules to CD4(+) T lymphocytes. J Exp Med (1999) 1.67
Murine dendritic cells pulsed in vitro with tumor antigen induce tumor resistance in vivo. Eur J Immunol (1994) 1.58
Evidence that multiple myeloma Ig heavy chain VDJ genes contain somatic mutations but show no intraclonal variation. Blood (1992) 1.42
Genes encoding tumor-specific antigens are expressed in human myeloma cells. Blood (1999) 1.37
Organ involvement and phenotypic adhesion profile of 5T2 and 5T33 myeloma cells in the C57BL/KaLwRij mouse. Br J Cancer (1997) 1.30
Role of CD8alpha+ and CD8alpha- dendritic cells in the induction of primary immune responses in vivo. J Leukoc Biol (1999) 1.30
Induction of effective therapeutic antitumor immunity by direct in vivo administration of lentiviral vectors. Gene Ther (2006) 1.30
Biclonal B-cell lymphoma. N Engl J Med (1984) 1.27
Human dendritic cell responses to lipopolysaccharide and CD40 ligation are differentially regulated by interleukin-10. Eur J Immunol (1997) 1.27
Lentiviral vectors for cancer immunotherapy: transforming infectious particles into therapeutics. Gene Ther (2007) 1.27
Image-based point spread function implementation in a fully 3D OSEM reconstruction algorithm for PET. Phys Med Biol (2010) 1.24
Interleukin-10 prevents the generation of dendritic cells from human peripheral blood mononuclear cells cultured with interleukin-4 and granulocyte/macrophage-colony-stimulating factor. Eur J Immunol (1997) 1.24
Mechanism and kinetics of factor VIII inactivation: study with an IgG4 monoclonal antibody derived from a hemophilia A patient with inhibitor. Blood (1998) 1.22
Endogenously produced substance P contributes to lymphocyte proliferation induced by dendritic cells and direct TCR ligation. Eur J Immunol (1999) 1.16
Evidence that the clonogenic cell in multiple myeloma originates from a pre-switched but somatically mutated B cell. Br J Haematol (1994) 1.14
Interleukin-12-activated natural killer cells recognize B7 costimulatory molecules on tumor cells and autologous dendritic cells. Blood (1998) 1.12
A MAGE-A3 peptide presented by HLA-DP4 is recognized on tumor cells by CD4+ cytolytic T lymphocytes. Cancer Res (2000) 1.12
Strategies for production of monoclonal anti-idiotype antibodies against human B cell lymphomas. J Immunol (1984) 1.06
Decreased CD40 ligand induction in CD4 T cells and dysregulated IL-12 production during HIV infection. Clin Exp Immunol (1999) 1.05
Electroporation of immature and mature dendritic cells: implications for dendritic cell-based vaccines. Gene Ther (2005) 1.05
Detection of monoclonal B lymphocytes in bone marrow and peripheral blood of multiple myeloma patients by immunoglobulin gene rearrangement studies. Br J Haematol (1989) 1.00
A human antibody directed to the factor VIII C1 domain inhibits factor VIII cofactor activity and binding to von Willebrand factor. Blood (2000) 1.00
Development of the Nanobody display technology to target lentiviral vectors to antigen-presenting cells. Gene Ther (2012) 0.99
Idiotype vaccination against murine B cell lymphoma. Humoral and cellular responses elicited by tumor-derived immunoglobulin M and its molecular subunits. J Immunol (1987) 0.98
CD40 ligation prevents Trypanosoma cruzi infection through interleukin-12 upregulation. Infect Immun (1999) 0.97
Human pancreatic duct cells can produce tumour necrosis factor-alpha that damages neighbouring beta cells and activates dendritic cells. Diabetologia (2004) 0.96
Clonally related IgA- and IgE-secreting plasma cells in a myeloma patient. Eur J Haematol (2000) 0.95
Ly-1 (CD5), a membrane glycoprotein of mouse T lymphocytes and a subset of B cells, is a natural ligand of the B cell surface protein Lyb-2 (CD72). J Immunol (1992) 0.94
Retrovirally transduced bone marrow-derived dendritic cells require CD4+ T cell help to elicit protective and therapeutic antitumor immunity. J Immunol (1999) 0.94
A phase IB study on intravenous synthetic mRNA electroporated dendritic cell immunotherapy in pretreated advanced melanoma patients. Ann Oncol (2013) 0.94
CD40 engagement on endothelial cells promotes tissue factor-dependent procoagulant activity. Thromb Haemost (1998) 0.93
Dendritic cells fused with mastocytoma cells elicit therapeutic antitumor immunity. Int J Cancer (1998) 0.93
IL-12 prevents neonatal induction of transplantation tolerance in mice. Eur J Immunol (1998) 0.92
CD45RO+ memory T cells but not CD45RA+ naive T cells can be efficiently activated by remote co-stimulation with B7. Int Immunol (1993) 0.91
Expression of B7-1 by highly metastatic mouse T lymphomas induces optimal natural killer cell-mediated cytotoxicity. Cancer Res (1995) 0.91
Treatment of mice bearing BCL1 lymphoma with bispecific antibodies. J Immunol (1991) 0.89
CD40L-induced IL-12 production is further enhanced by the Th2 cytokines IL-4 and IL-13. Scand J Immunol (2001) 0.89
Granulocyte-macrophage colony-stimulating factor: involvement in control of Trypanosoma cruzi infection in mice. Infect Immun (1996) 0.88
Immunoglobulins D and M multiple myeloma variants are heavily mutated. Clin Cancer Res (1997) 0.88
Activation of murine T cells by bacterial superantigens requires B7-mediated costimulation. Cell Immunol (1995) 0.88
Autoimmune lymphoproliferative syndrome type III, an indefinite disorder. Leuk Lymphoma (2001) 0.87
Immunoglobulin VH gene sequence analysis of spontaneous murine immunoglobulin-secreting B-cell tumours with clinical features of human disease. Immunology (1998) 0.86
Co-stimulation lowers the threshold for activation of naive T cells by bacterial superantigens. Int Immunol (1995) 0.86
The effect of regularization in motion compensated PET image reconstruction: a realistic numerical 4D simulation study. Phys Med Biol (2013) 0.84
Induction of antigen-specific CD8+ cytotoxic T cells by dendritic cells co-electroporated with a dsRNA analogue and tumor antigen mRNA. Gene Ther (2006) 0.83
Myeloma isotype-switch variants in the murine 5T myeloma model: evidence that myeloma IgM and IgA expressing subclones can originate from the IgG expressing tumour. Leukemia (2001) 0.83
Lentiviral vectors: a versatile tool to fight cancer. Curr Mol Med (2013) 0.82
Inhibition of the CD40 pathway of monocyte activation by triazolopyrimidine. Clin Immunol (1999) 0.82
Production and characterization of bispecific single-chain antibody fragments. Mol Immunol (1995) 0.81
Vaccination with tumor-antigen-pulsed dendritic cells induces in vivo resistance to a B cell lymphoma. Adv Exp Med Biol (1993) 0.81
Extracting a respiratory signal from raw dynamic PET data that contain tracer kinetics. Phys Med Biol (2014) 0.81
CD40 engagement induces monocyte procoagulant activity through an interleukin-10 resistant pathway. Eur J Immunol (1996) 0.81
Tumorigenicity of mouse T lymphoma cells is controlled by the level of major histocompatibility complex class I H-2Kk antigens. Clin Exp Metastasis (1994) 0.80
Interleukin-12-secreting human papillomavirus type 16-transformed cells provide a potent cancer vaccine that generates E7-directed immunity. Int J Cancer (1999) 0.80
Effects of granulocyte-macrophage colony-stimulating factor and tumor necrosis factor alpha on Trypanosoma cruzi trypomastigotes. Infect Immun (1998) 0.80
In vivo retargeting of T cell effector function by recombinant bispecific single chain Fv (anti-CD3 x anti-idiotype) induces long-term survival in the murine BCL1 lymphoma model. J Immunol (1998) 0.80
Interferon-beta inhibits Th1 responses at the dendritic cell level. Relevance to multiple sclerosis. Acta Neurol Belg (1999) 0.79
Induction of tumor immunity by autologous B lymphoma cells expressing a genetically engineered idiotype. Gene Ther (1999) 0.79
Downregulation of Stat3 in melanoma: reprogramming the immune microenvironment as an anticancer therapeutic strategy. Gene Ther (2013) 0.79
IFN-beta interferes with the differentiation of dendritic cells from peripheral blood mononuclear cells: selective inhibition of CD40-dependent interleukin-12 secretion. J Interferon Cytokine Res (1999) 0.79
Implementation and evaluation of a 3D one-step late reconstruction algorithm for 3D positron emission tomography brain studies using median root prior. Eur J Nucl Med Mol Imaging (2001) 0.79
Southern blot analysis in a case of Richter's syndrome. Evidence for a postrearrangement heavy chain gene deletion associated with the altered phenotype. Am J Clin Pathol (1991) 0.79
Persistence of residual tumour cells after cytokine-mediated ex vivo expansion of mobilized CD34+ blood cells in multiple myeloma. Br J Haematol (1997) 0.78
Immune changes induced by electroconvulsive therapy (ECT). Ann N Y Acad Sci (1992) 0.78
Syngeneic antiidiotypic immune responses to a B cell lymphoma. Comparison between heavy chain hypervariable region peptides and intact Ig as immunogens. J Exp Med (1985) 0.78
The genetic variability of the VH genes in follicular lymphoma: the impact of the hypermutation mechanism. Br J Haematol (1999) 0.78
Revision of the diagnosis of T-zone lymphoma in the father of a patient with autoimmune lymphoproliferative syndrome type II. Br J Haematol (1999) 0.78
Role of T-cell subsets in the bispecific antibody (anti-idiotype x anti-CD3) treatment of the BCL1 lymphoma. Cancer Res (1994) 0.78
Enhanced 3D PET OSEM reconstruction using inter-update Metz filtering. Phys Med Biol (2000) 0.78
B7-1, IFN gamma and anti-CTLA-4 co-operate to prevent T-cell tolerization during immunotherapy against a murine T-lymphoma. Int J Cancer (2000) 0.77
Native soluble CD5 delivers a costimulatory signal to resting human B lymphocytes. Cell Immunol (1996) 0.77
Bispecific antibody therapy of two murine B-cell lymphomas. Int J Cancer Suppl (1992) 0.77
The clonogenic precursor cell in multiple myeloma. Leuk Lymphoma (1995) 0.77
Specific killing of lymphoma cells by cytotoxic T-cells mediated by a bispecific diabody. Protein Eng (1996) 0.77
Treatment of murine B cell lymphoma with bispecific monoclonal antibodies (anti-idiotype x anti-CD3). J Immunol (1991) 0.77
Bispecific antibody-mediated immunotherapy of the BCL1 lymphoma: increased efficacy with multiple injections and CD28-induced costimulation. Blood (1996) 0.77
Metastasis of mouse T lymphoma cells is controlled by the level of major histocompatibility complex class I H-2Dk antigens. Int J Cancer (1994) 0.76
Selective response of CD5+ B cell malignancies to activation of the CD72 antigen. Clin Immunol Immunopathol (1998) 0.76
Fighting with the enemy's weapons? the role of costimulatory molecules in HIV. Curr Mol Med (2011) 0.76
Unexpected effects of viral interleukin-10-secreting dendritic cells in vivo: preferential inhibition of TH2 responses. Transplant Proc (2004) 0.76
Active antitumor immunotherapy, with or without B7-mediated costimulation, increases tumor progression in an immunogenic murine T cell lymphoma model. Cancer Immunol Immunother (1998) 0.76
Use of quantitative ASO-PCR to predict relapse in multiple myeloma. Br J Haematol (1999) 0.75
In vivo studies using bispecific antibodies (anti-CD3 x anti-idiotype) and CD28-induced costimulation in the BCL1 lymphoma. J Hematother (1995) 0.75
Costimulation regulates the kinetics of interleukin-2 response to bacterial superantigens. Immunology (1996) 0.75
Rapid processing of PET list-mode data for efficient uncertainty estimation and data analysis. Phys Med Biol (2016) 0.75
Isotype switch and idiotype variation in hairy cell leukemia. Leukemia (1990) 0.75
Dendritic cells can be used as physiological adjuvant in vivo. Adv Exp Med Biol (1995) 0.75
CD80 (B7-1) and CD86 (B7-2): potential targets for immunotherapy? Res Immunol (1996) 0.75
The use of the anti-malaria drug Fansidar (pyrimethamine and sulphadoxine) in the treatment of a patient with autoimmune lymphoproliferative syndrome and Fas deficiency. Br J Haematol (1998) 0.75
Major depressive disorder, endogeneicity and natural killer cell numbers and activity. Int J Neurosci (1990) 0.75
A MAGE-3 peptide presented by HLA-B44 is also recognized by cytolytic T lymphocytes on HLA-B18. Tissue Antigens (2002) 0.75